Clik here to view.
CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP...
SHANGHAI CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces...
View ArticleClik here to view.
ERS上呈报的CONVERT临床试验数据显示，AeriSeal系统治疗晚期慢性阻塞性肺病/肺气肿患者取得初步成功
加州红木城和西班牙巴塞罗那 (美国商业资讯)–Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”)是重症肺病微创治疗领域的全球领导者，公司宣布在欧洲呼吸学会(ERS)...
View ArticleClik here to view.
Bertis Announces Proteomic Based Research Results of New Biomarker for...
SEONGNAM, South Korea Bertis, a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced on the 5th that the research results of their...
View ArticleClik here to view.
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that BTK inhibitor orelabrutinib has been granted...
View ArticleClik here to view.
Orum Therapeutics to Participate at Investor Conferences in September
BOSTON & DAEJEON, South Korea Orum Therapeutics, a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced...
View ArticleClik here to view.
ERSで発表されたCONVERT臨床試験のデータは進行期COPD／肺気腫患者におけるAeriSealシステムの初期段階での成功を実証
米カリフォルニア州レッドウッドシティ & スペイン・バルセロナ （ビジネスワイヤ） — 重症肺疾患に対する低侵襲治療の世界的リーダー企業であるプルモンクス・コーポレーション（Nasdaq:...
View ArticleClik here to view.
Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision...
TEL AVIV, Israel & MELBOURNE, Australia Azura Ophthalmics Ltd. (Azura), a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Lenalidomide Capsules in the...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today...
View ArticleClik here to view.
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3...
PARIS & CAMBRIDGE, Mass. & SHANGHAI, China & PRINCETON, N.J. Regulatory News: NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), a late-stage clinical biotechnology company pioneering...
View ArticleClik here to view.
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and...
View ArticleClik here to view.
Genexine’s First-in-Class Therapeutic DNA Vaccine Shows Significant Potential...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of...
BEIJING InnoCare Pharma (HKEX: 09969) announced today that the first patient was dosed in the phase II registrational trial (Registry number: CTR20221519) of tafasitamab in combination with...
View ArticleClik here to view.
Exscientia将参加于9月份召开的投资者会议
英格兰牛津 (美国商业资讯)–Exscientia (Nasdaq: EXAI)今天宣布，公司管理层将于9月份出席以下投资者会议： 摩根士丹利全球医疗年会： 日期：2022年9月14日（周三） 时间：英国夏令时间下午3:35/美国东部时间上午10:35 地点：纽约州纽约市 参会人员：首席财务官兼首席战略官Ben Taylor和首席运营官Dave Hallett 美银证券全球医疗会议：...
View ArticleClik here to view.
エクセンシアが9月に開催される投資家会議に参加
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq：EXAI）は本日、当社経営陣が9月に開催される下記の投資家会議に参加すると発表しました： モルガン・スタンレー年次グローバル・ヘルスケア会議： 開催日：2022年9月14日（水） 時刻：英国時間午後3時35分、米国東部時間午前10時35分 場所：ニューヨーク州ニューヨーク 参加者：Ben...
View ArticleClik here to view.
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
DS-7300 Continues to Show Promising Durable Response in Patients with Several...
TOKYO, BASKING RIDGE, N.J. & NASHVILLE, Tenn. Daiichi Sankyo (TSE: 4568) and Sarah Cannon Research Institute (SCRI) announced that extended follow-up data from a phase 1/2 trial of DS-7300, a...
View ArticleClik here to view.
ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in...
TOKYO & BASKING RIDGE, N.J. Detailed positive results from an interim analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated clinically meaningful...
View ArticleClik here to view.
Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive...
TOKYO & HANGZHOU, China & SHANGHAI Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting...
View ArticleClik here to view.
Rhizen Pharmaceuticals...
スイス・バーゼル （ビジネスワイヤ） — スイスに拠点を置く非公開の臨床段階バイオ製薬企業であるRhizen Pharmaceuticals AG（Rhizen）は本日、2022年9月9～13日にパリで開催予定のESMO 2022において、局所進行性／転移性乳がんを対象に進行中のテナリシブの第2相試験のデータおよび完了したRP12146の用量漸増相試験のデータを報告すると発表しました。...
View ArticleClik here to view.
AnHeart Therapeutics and NewG Lab Therapeutics Receive Orphan Drug...
NEW YORK & SEOUL, South Korea AnHeart Therapeutics and NewG Lab Therapeutics, a subsidiary of NewG Lab Pharma, announced that the Ministry of Food and Drug Safety (MFDS), Republic of Korea has...
View Article